Bright Minds Biosciences Inc. (DRUG) intrinsic value & 10-year financials
Bright Minds Biosciences Inc. (DRUG) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2024)
- —
- ROIC (10-yr avg)
- -88.4%
- Free cash flow (FY2024)
- —
DRUG 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | — | -CAD 2.8M | -CAD 0.65 | — | — | -46.2% |
| FY2023 | — | -CAD 7.4M | -CAD 1.98 | — | — | -86.0% |
| FY2022 | — | -CAD 15.0M | -CAD 1.21 | — | — | -100.0% |
| FY2021 | — | -CAD 8.7M | -CAD 0.96 | — | — | -85.9% |
| FY2020 | — | -CAD 480.4K | -CAD 0.13 | — | — | -124.0% |
| FY2019 | — | — | — | — | — | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in CAD.
Executive summary
BRIGHT MINDS BIOSCIENCES INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BRIGHT MINDS BIOSCIENCES INC. 10-year average ROIC is N/A; capital efficiency cannot be assessed from the available history.
BRIGHT MINDS BIOSCIENCES INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BRIGHT MINDS BIOSCIENCES INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.